Ind-Swift Laboratories Limited Market Cap ($347.99 Million)
Market Cap & Net Worth: Ind-Swift Laboratories Limited (INDSWFTLAB)
Ind-Swift Laboratories Limited market cap. Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) has a market capitalization of $347.99 Million (Rs32.18 Billion) as of November 5, 2026. Listed on the NSE stock exchange, this India-based company holds position #13843 globally and #687 in its home market, demonstrating a 0.47% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ind-Swift Laboratories Limited's stock price Rs370.55 by its total outstanding shares 86836558 (86.84 Million). Also see Ind-Swift Laboratories Limited (INDSWFTLAB) cash conversion ratio for how efficiently the company converts equity into cash flow.
Ind-Swift Laboratories Limited Market Cap History (2015–2026)
Ind-Swift Laboratories Limited market cap history from 2015 to 2026. Data shows growth from $34.84 Million to $347.99 Million (23.64% CAGR). Check INDSWFTLAB stock price for real-time trading data and today's change.
Ind-Swift Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ind-Swift Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Ind-Swift Laboratories Limited to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.01x
Ind-Swift Laboratories Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Ind-Swift Laboratories Limited's market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $34.00 Million | $6.53 Billion | -$586.88 Million | 0.01x | N/A |
| 2017 | $71.94 Million | $6.97 Billion | -$391.34 Million | 0.01x | N/A |
| 2018 | $45.69 Million | $7.65 Billion | $219.76 Million | 0.01x | 0.21x |
| 2019 | $21.98 Million | $7.57 Billion | $289.46 Million | 0.00x | 0.08x |
| 2020 | $58.46 Million | $7.80 Billion | -$211.88 Million | 0.01x | N/A |
| 2021 | $63.81 Million | $8.91 Billion | -$31.47 Million | 0.01x | N/A |
| 2022 | $65.22 Million | $10.39 Billion | -$21.49 Million | 0.01x | N/A |
| 2023 | $97.24 Million | $12.07 Billion | $475.97 Million | 0.01x | 0.20x |
| 2024 | $101.96 Million | $12.81 Billion | $4.21 Billion | 0.01x | 0.02x |
| 2025 | $82.78 Million | $5.62 Billion | $2.50 Billion | 0.01x | 0.03x |
Competitor Companies of INDSWFTLAB by Market Capitalization
Companies near Ind-Swift Laboratories Limited in the global market cap rankings as of November 5, 2026. Also see Ind-Swift Laboratories Limited total assets for a full breakdown of the balance sheet.
Key companies related to Ind-Swift Laboratories Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Ind-Swift Laboratories Limited (2015–2026)
Market capitalization of Ind-Swift Laboratories Limited from 2015 to today. Between 2015 and today, Ind-Swift Laboratories Limited's market cap moved from $34.84 Million to $ 347.99 Million, with a yearly change of 23.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs347.99 Million | +320.36% |
| 2025 | Rs82.78 Million | -18.81% |
| 2024 | Rs101.96 Million | +4.85% |
| 2023 | Rs97.24 Million | +49.10% |
| 2022 | Rs65.22 Million | +2.21% |
| 2021 | Rs63.81 Million | +9.16% |
| 2020 | Rs58.46 Million | +166.03% |
| 2019 | Rs21.98 Million | -51.90% |
| 2018 | Rs45.69 Million | -36.49% |
| 2017 | Rs71.94 Million | +111.60% |
| 2016 | Rs34.00 Million | -2.43% |
| 2015 | Rs34.84 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Ind-Swift Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $347.99 Million USD |
| MoneyControl | $347.99 Million USD |
| MarketWatch | $347.99 Million USD |
| marketcap.company | $347.99 Million USD |
| Reuters | $347.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more